HK$84.75
2.70%
Hong Kong, Nov 13, 04:08 pm HKT. Closed.
ISIN
KYG4818G1010
Symbol
1801
Index

Innovent Biologics Stock price

HK$84.75
-7.20 7.83% 1M
-2.30 2.64% 6M
+8.50 11.15% YTD
-7.20 7.83% 1Y
+40.70 92.40% 3Y
+8.70 11.44% 5Y
+68.17 411.16% 10Y
+68.17 411.16% 20Y
Hong Kong, Closing price Fri, Nov 13 2026
-2.35 2.70%
ISIN
KYG4818G1010
Symbol
1801
Index
Industry

Is Innovent Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$152.2b
Enterprise Value
HK$131.4b
Net debt
positive
Cash
HK$23.5b
Shares outstanding
1.7b
Valuation
P/E
105.9
P/S | estimate
8.2 | 6.8
EV/Sales | estimate
7.1 | 5.9
EV/FCF | ex SBC
12.0 | 12.6
P/B
6.2
Financial Health
Equity Ratio
51.8%
Return on Equity
4.2%
ROCE
5.4%
ROIC
10.7%
Debt/Equity
0.1
Financials
Revenue | estimate
HK$18.5b | HK$22.3b
EBITDA
-
EBIT
HK$2.0b
Net Income
HK$1.4b
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
37.5% | 45.1%
EBITDA
-
EBIT
27.8%
Net Income
8.8%
Free Cash Flow
-
Margin
Gross
85.9%
EBITDA
-
EBIT
11.0%
Net
7.9%
Free Cash Flow | ex SBC
- | -
More
EPS
HK$0.8
FCF per Share
-
Short interest
-
Employees
8k
Rev per Employee
HK$2.0m

Innovent Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Innovent Biologics forecast:

33x Buy
92%
3x Hold
8%

Analyst Opinions

36 Analysts have issued a Innovent Biologics forecast:

Buy
92%
Hold
8%

Financial data from Innovent Biologics

Jun '26
+/-
%
18,470 18,470
38% 38%
100%
- Direct Costs 2,609 2,609
36% 36%
14%
15,861 15,861
38% 38%
86%
- Selling and Administrative Expenses 8,882 8,882
32% 32%
48%
- Research and Development Expense 3,880 3,880
56% 56%
21%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 2,032 2,032
28% 28%
11%
Net Profit 1,449 1,449
9% 9%
8%

In millions HKD.

Don't miss a Thing! We will send you all news about Innovent Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innovent Biologics Stock News

Neutral
PRNewsWire
●
about 19 hours ago
PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced that seven innovative products of Innovent were successfu...
Neutral
PRNewsWire
●
2 days ago
PALO ALTO, Calif. and SUZHOU, China, Nov. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular, and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical da...
Neutral
PRNewsWire
●
6 days ago
PALO ALTO, Calif. and SUZHOU, China, Nov. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announced today that its self-developed recombinant f...
More Innovent Biologics News

Company Profile

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.

Head office China
CEO Dr. Yu
Employees 7,502
Website www.innoventbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today